Influenza A virus H5N1 vaccine(Medicago, Inc.)(Influenza A virus H5N1 vaccine(Medicago, Inc.)) - 药物靶点：HN_在研适应症：禽流感_专利_临床

概要

基本信息

药物类型

病毒样颗粒疫苗、预防性疫苗

别名

H5N1 VLP vaccine、Influenza A virus H5N1 vaccine (Medicago)、One-dose H5N1 VLP vaccine

+ [4]

靶点

HN

作用机制

HN抑制剂(血凝素-神经氨酸酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Infectious Disease Research Institute

非在研机构

Medicago, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的临床试验

NCT01991561 / Completed临床2期

Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.

A phase 2, Randomized, Observer-blind, Multicenter, Dose-Ranging Study to Evaluate the Immunogenicity, Safety, and Tolerability of the plant-made H5 VLP Influenza vaccine adjuvanted with Alhydrogel or Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE), in healthy adults 18-60 years of age.

开始日期2013-06-01

申办/合作机构

Medicago, Inc.

[+2]

NCT01657929 / Completed临床1期IIT

A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pandemic influenza. The vaccine, identified as H5-VLP + GLA-AF, consists of a recombinant influenza virus H5 protein (hemagglutinin from A/Indonesia/5/2005) produced in a plant-based expression system assembling into virus-like particles together with the adjuvant GLA-AF.

开始日期2012-09-01

申办/合作机构

Access To Advanced Health Institute

[+1]

NCT01244867 / Completed临床2期

A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.

The primary objective is to assess the immunogenicity and safety and tolerability of two consecutive doses of H5 VLP Influenza vaccine given 21 days apart, at three dose levels: in part A: 20 µg, 30 µg and 45 µg combined with Alhydrogel® 1%, or 45 µg without Alhydrogel®, compared to the placebo, (100mM phosphate buffer + 150mM NaCl + 0.01% Tween 80).

开始日期2010-11-01

申办/合作机构

Medicago, Inc.

[+1]

100 项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的专利（医药）

登录后查看更多信息

45

项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的文献（医药）

2024-12-31·Emerging microbes & infections

A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage

Article

作者: Ye, Hejia ; He, Yanjuan ; Ao, Xiang ; Fan, Huiying ; Liao, Ming ; Qiu, Weihong ; Wang, Jiaxin ; Chi, Lanyan ; Zhu, Xiutong ; Kong, Dexin

2024-12-31·Human Vaccines & Immunotherapeutics

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

Review

作者: Ruiz-Aragón, Jesús ; Nguyen, Van Hung ; Levin, Myron J ; Pelton, Stephen I ; Mould-Quevedo, Joaquin F ; Urueña, Analia ; Giglio, Norberto ; Fisman, David ; Postma, Maarten

2024-01-01·GMS Hygiene and Infection Control

Cell-based influenza vaccines: An effective vaccine option for under 60-year-olds.

Review

作者: Schmidt, Kim J ; Wahle, Klaus ; Wendt, Luise ; Gärtner, Barbara C ; Beier, Dietmar ; Gosch, Gunther ; Förster, Laura-Christin ; Schwarz, Tino F

100 项与 Influenza A virus H5N1 vaccine(Medicago, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲型流感病毒感染	临床2期	加拿大	Medicago, Inc.	2010-11-21
禽流感	临床2期	-	Infectious Disease Research Institute	-
禽流感	临床2期	-	Medicago, Inc.	-
H5N1流感	临床1期	美国	Medicago, Inc.	2012-09-01